Trade Report: Today, Fishman Jay A Ltd. MI Sold shares of Allergan PLC (AGN)

Today, Fishman Jay A Ltd. MI Sold shares of Allergan PLC (AGN)

Fishman Jay A Ltd. MI reduced its stake in shares of Allergan PLC (NYSE:AGN) by 5.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,598 shares of the company’s stock after selling 5,765 shares during the period. Allergan PLC makes up 5.7% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 4th largest position. Fishman Jay A Ltd. MI’s holdings in Allergan PLC were worth $23,169,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Berson & Corrado Investment Advisors LLC boosted its position in shares of Allergan PLC by 79.6% in the second quarter. Berson & Corrado Investment Advisors LLC now owns 24,346 shares of the company’s stock valued at $5,626,000 after buying an additional 10,792 shares in the last quarter. Exxonmobil Investment Management Inc. TX boosted its position in shares of Allergan PLC by 6.5% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 102,390 shares of the company’s stock valued at $23,661,000 after buying an additional 6,293 shares in the last quarter. Thompson Rubinstein Investment Management Inc. OR purchased a new position in shares of Allergan PLC during the second quarter valued at about $681,000. Edge Wealth Management LLC boosted its position in shares of Allergan PLC by 113.1% in the second quarter. Edge Wealth Management LLC now owns 895 shares of the company’s stock valued at $206,000 after buying an additional 475 shares in the last quarter. Finally, NEXT Financial Group Inc boosted its position in shares of Allergan PLC by 77.6% in the second quarter. NEXT Financial Group Inc now owns 1,817 shares of the company’s stock valued at $419,000 after buying an additional 794 shares in the last quarter. Hedge funds and other institutional investors own 86.89% of the company’s stock.

Allergan PLC (NYSE:AGN) traded down 0.54% during mid-day trading on Monday, hitting $191.19. 2,211,586 shares of the stock were exchanged. Allergan PLC has a one year low of $184.50 and a one year high of $322.68. The company has a 50-day moving average price of $212.72 and a 200-day moving average price of $233.35. The company has a market cap of $71.71 billion, a P/E ratio of 5.36 and a beta of 1.08.

Allergan PLC (NYSE:AGN) last issued its earnings results on Wednesday, November 2nd. The company reported $3.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. During the same quarter in the prior year, the firm posted $3.48 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. On average, analysts predict that Allergan PLC will post $13.37 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.70 per share. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 annualized dividend and a dividend yield of 1.46%.

AGN has been the topic of a number of recent analyst reports. William Blair reaffirmed a “market perform” rating on shares of Allergan PLC in a research note on Monday, November 21st. Mizuho lowered their price target on shares of Allergan PLC from $305.00 to $299.00 and set a “buy” rating on the stock in a research note on Tuesday, October 11th. Vetr raised shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $288.87 price target on the stock in a research note on Monday, August 22nd. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $300.00 price target on shares of Allergan PLC in a research note on Tuesday, September 27th. Finally, Argus reaffirmed a “buy” rating and set a $340.00 price target on shares of Allergan PLC in a research note on Tuesday, October 4th. Seven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $289.11.

In other news, CEO Brent L. Saunders purchased 5,250 shares of Allergan PLC stock in a transaction that occurred on Monday, November 21st. The stock was acquired at an average cost of $189.13 per share, for a total transaction of $992,932.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Maria Teresa Hilado purchased 1,422 shares of Allergan PLC stock in a transaction that occurred on Friday, November 11th. The stock was purchased at an average price of $210.64 per share, with a total value of $299,530.08. Following the completion of the purchase, the chief financial officer now directly owns 12,659 shares in the company, valued at $2,666,491.76. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.

About Allergan PLC

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Related posts

Leave a Comment